AkhtarAshfaqMDFACP, FASN
Nephrology • Miami, FLChronic Renal Failure & Dialysis, Hypertension, Renal Metabolism
Senior Vice President, Clinical R&D and Medical Affairs, OPKO Renal, Division of OPKO Pharmaceuticals, Miami, Florida
Dr. Ashfaq is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4400 Biscayne Blvd
Miami, FL 33137Phone+1 516-810-8680Fax+1 516-810-8680
Summary
- Dr. Akhtar Ashfaq is a nephrologist based in Miami, FL, specializing in chronic renal failure, dialysis, hypertension, and renal metabolism. He completed his nephrology fellowship at Zucker School of Medicine and an internal medicine residency at TriHealth, after obtaining his medical degree from Dow University of Health Sciences. Dr. Ashfaq is experienced in chronic kidney disease management, including various dialysis modalities and continuous renal replacement therapy. His research includes multiple publications on secondary hyperparathyroidism and vitamin D in chronic kidney disease, some of which have been cited by other researchers. Additionally, he has been involved in clinical trials related to secondary hyperparathyroidism and COVID-19 treatments.
Education & Training
Zucker School of Medicine at Hofstra/NorthwellFellowship, Nephrology, 1994 - 1996
TriHealth (Good Samaritan Hospital)Residency, Internal Medicine, 1991 - 1994
Dow University of Health SciencesClass of 1988
Certifications & Licensure
FL State Medical License 2020 - 2026
NY State Medical License 1995 - 2026
PA State Medical License 1996 - 2000
Clinical Trials
- Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism Start of enrollment: 2023 Jan 31
- Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 Start of enrollment: 2020 Nov 02
Publications & Presentations
PubMed
- Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidne...Akhtar Ashfaq, John Choe, Stephen A Strugnell, Nilay Patel, Stuart M Sprague
American Journal of Nephrology. 2025-02-21 - 2 citationsSustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyper...Charles W Bishop, Akhtar Ashfaq, Stephen A Strugnell, John Choe, Nilay Patel
American Journal of Nephrology. 2024-08-27 - Extended-Release Calcifediol: A Data Journey from Phase 3 Studies to Real-World Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism.Domenico Merante, Henrik Schou, Isabelle Morin, Marius Manu, Akhtar Ashfaq
Nephron. 2024-01-01
Journal Articles
- Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (ERC) in non-dia...Akhtar Ashfaq, John Cho, Stephen A. Strugnell, Nilay Patel, Stuart M. Sprague, Keith C. Norris, Edgar Lerma, P.Martin Petkovich, Charles W. Bishop, American Journalist of Nephrology, 2/21/2025
Authored Content
- Tubulointerstitial Nephritis and Uveitis Syndrome (TINU Syndrome)September 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
